Alpine Immune's Davoceticept Monotherapy Reduces Tumors In Early Stage Study

Alpine Immune Sciences Inc ALPN announced the oral presentation of results from the dose-escalation portion of NEON-1 study of davoceticept monotherapy in advanced malignancies.

  • The data were shared at the 2022 Annual Meeting of the American Association for Cancer Research (AACR).
  • Data showed that a heavily pretreated, advanced solid tumor population demonstrated tumor volume reduction.
  • 26 (54%) achieved clinical benefit as defined as a best response of stable disease or better. Three (6%) remained on treatment beyond six months. Two partial responses were observed in colorectal and renal cell carcinoma.
  • Last month, the FDA placed a partial clinical hold on Alpine Immune's NEON-2 trial of davoceticept / pembrolizumab combo in advanced malignancies.
  • Davoceticept was well-tolerated with no reported events of cytokine release syndrome. Adverse events included mild to moderate immune-related adverse events and infusion-related reactions.
  • Single dose-limiting toxicity of gastritis was observed at 3 mg/kg, but a maximum tolerated dose was not reached.
  • Immunophenotyping demonstrated favorable increases in activated and central memory T cells and reductions in regulatory T cells. Pharmacodynamic analyses suggest 1 or 3 mg/kg every 3 weeks as the optimal biological dose.
  • Monotherapy expansion cohorts in metastatic cutaneous melanoma, renal cell carcinoma, and PD-L1-positive tumors are planned.
  • Price Action: ALPN shares are down 2.19% at $7.60 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!